Substances in that category are banned at all times, not only during competition
If necessary, we may also recommend blood testing or liaising with your GP
Anyone using a GLP-1 drug should make sure they get it prescribed through a trusted health care provider
Based on the clinical trial population and the medications mechanism, individuals who may benefit most from retatrutide once it becomes available include: Adults with a BMI of 30 or greater (obesity) Adults with a BMI of 27 or greater who have weight-related conditions such as type 2 diabetes, hypertension, dyslipidemia, or sleep apnea Individuals who have not achieved adequate results with semaglutide or tirzepatide Patients seeking greater weight loss than what current medications provide Individuals with metabolic dysfunction-associated steatohepatitis (MASH) given the glucagon receptors role in liver fat metabolism Retatrutide may not be appropriate for individuals with a history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe gastrointestinal disorders, or a history of pancreatitis
Here are scenarios where staying on tirzepatide, adjusting the current protocol, or exploring other options makes more sense than switching to retatrutide